RxDoctor Payments Data

Sarah Thomas, MD

Rheumatology · Indianapolis, INNPI 1144298712

Payments from drug & device makers

$2,024in general payments, 2019–2025

Across 151 payments — averaging $13.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$472
  • AbbVie$291
  • Pfizer$252
  • Genentech USA, Inc.$214
  • Mallinckrodt Hospital Products Inc.$151
  • Bristol Myers Squibb$144
  • plus $500 from 9 others

What the payments were for

  • Food & beverage$2,00999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,024 in reported general payments places this provider in the 40th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,240,083
Medicare patients
350
Services billed
102,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept53$406,967
Humira(Cf) PenAdalimumab20$182,192
Cosentyx Sensoready PenSecukinumab19$170,829
Xeljanz XrTofacitinib Citrate22$131,520
KineretAnakinra22$122,391
OtezlaApremilast14$103,383
HumiraAdalimumab13$84,226
RinvoqUpadacitinib13$80,580
KevzaraSarilumab18$79,664
Teriparatide29$55,813
Hydroxychloroquine Sulfate391$16,731
MethotrexateMethotrexate Sodium322$11,321
Leflunomide172$9,483
Celecoxib199$8,515
Colchicine36$5,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Rinvoq$291$164,80626 claims
AmgenOtezla$472$103,38314 claims
Scilex Pharmaceuticals Inc.Colchicine$16$5,72736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →